Immix Biopharma: Seeking Catalysts To Propel Out Of Microcap Status (NASDAQ:IMMX)

Love Employee/iStock via Getty Images Topline Summary Immix Biopharma (NASDAQ:IMMX) is a biotech company focused on development of novel CAR-T and other cell-based therapies for cancers and heme disorders. They are joining a growing group of companies using natural killer cell-based immunotherapy, which remains promising but unproven. Still, IMMX has a bit more data than…

Read More

Mistras Group: Not A Buy Right Now (NYSE:MG)

Ake Ngiamsanguan/iStock via Getty Images Mistras Group (NYSE:MG) offers asset protection solutions. MG posted Q3 FY23 results, which I will analyze in this report. I think MG is not a buy right now. Due to increasing debt, stagnant revenue growth, and because of the technical chart. It would be risky to bet on MG right…

Read More

BioLineRx: Weighing Aphexda’s Breakthrough Against Financial Challenges (NASDAQ:BLRX)

anusorn nakdee BioLineRx Ltd. (NASDAQ:BLRX) is a biopharmaceutical company founded in 2003 with headquarters in Israel and offices in the US. BLRX’s shares are traded in NASDAQ and TASE. Notably, BLRX has developed Aphexda, motixafortide for injection, the first drug FDA-approved for stem cell mobilization in multiple myeloma patients in a decade. The FDA approved…

Read More

Duluth Holdings: 2024 Will Be The Make Or Break Year (NASDAQ:DLTH)

Joe Hendrickson/iStock Editorial via Getty Images Duluth Holdings Inc. (NASDAQ:DLTH) has struggled through a challenging macro environment in recent years amid declining sales and poor earnings. The apparel retailer just reported its latest quarterly result, which missed estimates while management offered soft guidance. The setup here doesn’t look good with the stock down more than…

Read More

Palo Alto Networks: Fully Valued (NASDAQ:PANW)

da-kuk Palo Alto Networks’ (NASDAQ:PANW) Q1 FY2024 results were somewhat soft, with NGS growth beginning to moderate and hardware sales normalizing. The company remains well positioned though, due to its large customer base and broad portfolio of solutions. In particular, XSIAM and SASE should drive growth going forward. The stock is starting to look fully…

Read More